XOMA (XOMA +1.05%) signs a deal for Oncobiologics to use XOMA's ADAPT fully human antibody...

|About: XOMA Corporation (XOMA)|By:, SA News Editor

XOMA (XOMA +1.05%) signs a deal for Oncobiologics to use XOMA's ADAPT fully human antibody technology platform to develop drugs for treating cancer and immune diseases. (PR)